BAL Lazio

HTA

HTA – Risorse

Pubblicato lunedì 5 Maggio 2014

Risorse generali e reti internazionali

European network for Health Technology Assessment (EUNETHTA)
Health Technology Assessment Database (Cochrane)
Health Technology Assessment international (HTAi)
International Information Network on New and Emerging Health Technologies (EuroScan)
International Network of Agencies of Health Technology Assessment (INAHTA)

EUROPA

Italia
Agenzia nazionale per i servizi sanitari regionali (Age.Na.S.)
Società Italiana di Health Technology Assessment (SIHTA)

Austria
Ludwig Boltzmann Institut für Health Technology Assessment (LBI of HTA)

Belgio
Belgian Federal Health Care Knowledge Centre (KCE)

Danimarca
Danish Institute for Health Services Research (DSI)

Finlandia
Finnish Office for Health Technology Assessment (FinOHTA)

Francia
Comité d´Evaluation et de Diffusion des Innovations Technologiques (CEDIT)
Haute Autorité de Santé (HAS)

Germania
German Agency for HTA at the German Institute for Medical Documentation and Information (DAHTA @DIMDI)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

Lettonia
Health Statistics and Medical Technologies State Agency (VSMTVA)

Lituania
State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania (VASPVT)

Norvegia
Norwegian Knowledge Centre for the Health Services (NOKC)

Paesi Bassi
Gezondheidsraad (GR)
The Medical and Health Research Council of The Netherlands (ZonMw)

Polonia
Agency for Health Technology Assessment in Poland (AHTAPol)

Regno Unito
Centre for Reviews and Dissemination (CRD)
Institute of Applied Health Sciences (IAHS)
National Institute for Health Research Health Technology Assessment Programme
Quality Improvement Scotland (NHS QIS)

Spagna
Agencia de Evaluación de Tecnologias Sanitarias (AETS)
Andalusian Agency for Health Technology Assessment (AETSA)
Galician Agency for Health Technology Assessment (AVALIA-T)
Catalan Agency for Health Technology Assessment and Research (CAHTA)
Basque Office for Health Technology Assessment (OSTEBA)

Svezia
Swedish Council on Technology Assessment in Health Care (SBU)

Svizzera
Medical Technology Unit – Swiss Federal Office of Public Health (MTU-SFOPH)

RESTO DEL MONDO

Argentina
Institute for Clinical Effectiveness and Health Policy (IECS)

Australia
Adelaide Health Technology Assessment (AHTA)
Medical Services Advisory Committee (MSAC)

Brasile
Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Ciência e Tecnologia (DECIT-CGATS)

Canada
Agence d´Évaluation des Technologies et des Modes d´Intervention en Santé (AETMIS)
Canadian Agency for Drugs and Technologies in Health (CADTH)
Institute of Health Economics (IHE)

Malesia
Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS)

Messico
Centro Nacional de Excelencia Tecnológica en Salud (CENETEC)

Nuova Zelanda
Health Services Assessment Collaboration (HSAC)

Taiwan
Center for Drug Evaluation (CDE)

USA
Agency for Healthcare Research and Quality (AHRQ)

Tagged ,

Lascia un commento

Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *

Accedi agli articoli

Alemany S, Avella-García C, Liew Z, et al. Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts. Eur J Epidemiol (2021). https://doi.org/10.1007/s10654-021-00754-4

Salazar de Pablo G et al. Universal and selective interventions to prevent poor mental health outcomes in young people: systematic review and meta-analysis. Harvard Review of Psychiatry 2021;29 (3) 196-215.

Currie JM et al. Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the covid-19 pandemic. JAMA Netw Open 2021;4(4):e216147.

Marson A, Burnside G, Appleton R, et al.; SANAD II collaborators. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021;397(10282):1375-1386.

Marson A, Burnside G, Appleton R, et al.; SANAD II collaborators. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021;397(10282):1363-1374.

Zichi C et al. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. Eur j Canc 2021;149:49-60.

Seidler AN et al.; on behalf of the International Liaison Committee On Resuscitation Neonatal Life Support Task Force. Umbilical cord management for newborns <34 weeks' gestation: a meta-analysis. Pediatrics 2021; 147 (3) e20200576.

Gabrhelík R et al. Cannabis use during pregnancy and risk of adverse birth outcomes: a longitudinal cohort study. Eur Addict Res 2020. doi: 10.1159/000510821e

Ouldali N et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. February 1, 2021. Epub ahead of print. doi:10.1001/jama.2021.0694

Una finestra sull’open access

  • BMC Family Practice
  • BMC Medical Education
  • BMC Nursing
  • BMJ Open
  • PLOS Medicine

Reset della password

Per favore inserisci la tua email. Riceverai una nuova password via email.